(IR) and metabolic syndrome (MS), which are com- mon in the aged (>40 years) population. There are reports suggesting that older patients have more severe disease compared to younger population. The present study was aimed to compare the char- acteristics of old versus younger NAFLD patients. Materials and Methods: The anthropometric, bio- chemical and histological parameters of 270 old and 243 young NAFLD patients were compared. Results: The old NAFLD cases (mean age: 50.09  7.26) compared to younger patients (mean age: 33.48  4.8) had higher anthropometric indices (waist circumference: 97.64  10.79 vs. 94.4  7.87; P = 0.0007, waist–hip ratio: 0.98  0.07 vs. 0.95  0.05; P < 0.0001, waist–height ratio: 0.6  0.07 vs. 0.57  0.05; P < 0.0001), higher fasting blood glucose (103.85  33.5 vs. 94.39  24.46; P = 0.001) and Homeostasis model assessment Insulin resistance (HOMA-IR) (3.18  3.22 vs. 2.44  1.3; P = 0.01), higher prevalence of hypertension (49.66% vs. 39.25%; P = 0.02) and fasting hyperglycemia (38.34% vs. 18.28%; P < 0.0001) but paradoxically had lower transaminitis (ALT: 44.73  15.29 vs. 59.84  37; P = 0.0001). However the mean (BMI) body mass index (27.6  3.52 vs. 27  2.89; P > 0.05), fasting insulin (11.31  6.29 vs. 10.7  5.46; P = 0.41), triglyceride (204.33  143.17 vs. 201  110.53; P = 0.8), HDL Cho- lesterol (42.94  17 vs. 44.16  15.93; P = 0.47), pre- valence of metabolic syndrome (50.44% vs. 41.3%; P = 0.19) and histological activity [Definite NASH: 47% vs. 41%; P = 0.41, Hepatic Fibrosis: 36.47% vs. 25.26%; P = 0.1] were not statistically different between the old and young NAFLD patients. Conclusion: The older NAFLD patients did not have more severe disease, despite higher anthropometric indices and metabolic risk factors compared to younger patients. Corresponding author: . E-mail: scb_gastro_dept@hotmail.com http://dx.doi.org/10.1016/j.jceh.2015.07.261 COMPARISON OF EFFECT OF TELMISARTAN AND WEIGHT REDUCTION ON HISTOLOGICAL ACTIVITY OF NONALCOHOLIC STEATOHEPATITIS: A ONE YEAR RANDOMISED CONTROL TRIAL Shahinul Alam, Jahangir Kabir, Golam Mustafa, S.K. M. Nazmul Hasan, A.K.M. Khorshed Alam Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh Background and Aim: Both Telmisartan and weight reduction may affect nonalcoholic fatty liver disease activity score (NAS). We have designed this study to compare effect of Telmisartan and weight reduction on NAS. Materials and Methods: A total 50 nonalcoholic steatohepatitis (NASH) patients were randomized; 35 treated with Telmisartan 40 mg once daily with life style modification (TL) and 15 advised for only life style modification (L) for one year. At the end, 20 TL and 11 L were available for analysis. Results: Base line NAS, ALT, AST, insulin resistance index, component of metabolic syndrome, age, and sex were similar in both groups. There were signifi- cant improvement of steatosis P < .001, lobular inflammation P < .001, and ballooning P < .001 in TL group but in L group there was no improvement of steatosis and lobular inflammation. Body weight 10% reduced in 14 patients of whom 10 (50.00%) and 4 (36.4%) were from TL and L group, respectively. Nonreduction of body weight reflects no improve- ment of steatosis but reduction of weight influences improvement of all aspects of NAS. NAS improve- ment 2 was achieved in 7 (43.8%) intervened with Telmisartan only, 6 (37.5%) with Telmisartan and weight reduction, 3 (18.8%) with only weight reduc- tion, and in none with neither weight reduction nor on Telmisartan. Conclusion: Both Telmisartan and weight reduction improve NAS. But Telmisartan has a stronger effect. Corresponding author: Shahinul Alam. E-mail: shahinul67@yahoo.com http://dx.doi.org/10.1016/j.jceh.2015.07.262 CARDIOMETABOLIC RISK FACTORS IN ASYMPTOMATIC SCHOOL CHILDREN: SIGNIFICANCE OF REDEFINING ALT LIMITS Payal Patel, Nikhil Patel Shri A.N. Patel P.G. Institute, Anand, Gujarat, India Background: Childhood obesity and non-alcoholic fatty liver disease (NAFLD) are increasing globally. Nurturing of cardiometabolic risk factors (CMRF) in childhood can lead to atherogenic and metabolic complications later. ALT is a surrogate marker for NAFLD, which is part of a metabolic syndrome. This prospective observational study was planned to define prevalence of CMRF and NAFLD and whether ALT can predict CMRF. NON-ALCOHOLIC FATTY LIVER DISEASE S22 © 2015, INASL NAFLD